About

Precision radio­pharma­ceuticals

Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid-derived single-domain antibodies (sdAb) labeled with radioisotopes.

The company’s lead product, CAM-H2, is being evaluated in a Phase I/II trial targeting metastatic HER2-positive cancer. Patients with tumors that overexpress HER2 can benefit from effective targeted treatments today yet have a poor prognosis when the cancer spreads. CAM-H2 aims to effectively irradiate cancer lesions while sparing healthy tissue, based on its unique technology platform that leverages the favorable tissue distribution of sdAbs.

The company’s technology platform also allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy. In addition to CAM-H2, the company has two product candidates in preclinical stage and is further broadening its platform through research on isotopes, linker technology and combination therapies.

History

2014
Camel-IDS incorporation
EUR 1M grant
2015
Seed financing
EUR 1M grant
2016
Start FIH study
2017
Seed financing to EUR 3M
CEO joins company
2018
EUR 37M series A
Completion FIH study
2019
Preparation Phase I/II study
EUR 0.8M grant
2020
IND approval Phase I/II study

Your browser is not supported. Update your browser for more security, speed and to make the most of this site.